Oct 2021 Articles

Articles
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Majithia A, Bhatt DL, Friedman AN, et al.
Journal:
Circulation

First published: October 28, 2021 DOI: 10.1161/CIRCULATIONAHA.121.055560
View
- Share
Articles
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Verma S, Bhatt DL, Steg PG, et al.
Journal:
Circulation

First published: October 28, 2021 DOI: 10.1161/CIRCULATIONAHA.121.056290
View
- Share
Articles
European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology
Suleman Aktaa, Baris Gencer, Elena Arbelo, et al.
Journal:
Eur J Prev Cardiol

First published: October 23, 2021 DOI: 10.1093/eurjpc/zwab160
View
- Share
Articles
Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
Azita H Talasaz, Ai-Chen Jane Ho, Fawzia Bhatty, et al.
Journal:
Pharmacotherapy

First published: October 17, 2021 DOI: 10.1002/phar.2635
View
- Share
Articles
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, et al.
Journal:
Arteriosclerosis, Thrombosis, and Vascular Biology

First published: October 14, 2021 DOI: 10.1161/ATV.0000000000000147
View
- Share
Articles
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT
Kazuma Oyama, Robert P Giugliano, Michael A Blazing et al.
Journal:
Journal of the American College of Cardiology Volume 78, Issue 15, 12 October 2021, Pages 1499-1507

First published: October 12, 2021 DOI: 10.1016/j.jacc.2021.08.011
View
- Share
Articles
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
Kausik K Ray, Laurens F Reeskamp, Ulrich Laufs, et al.
Journal:
European Heart Journal

First published: October 12, 2021 DOI: 10.1093/eurheartj/ehab718
View
- Share
Articles
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Journal:
J Am Coll Cardiol

First published: October 12, 2021 DOI: 10.1016/j.jacc.2021.08.009
View
- Share
Articles
Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data
Kwon O, Na W, Hur J, et al.
Journal:
Cardiovasc Drugs Ther

First published: October 8, 2021 DOI: 10.1007/s10557-021-07255-2
View
- Share
Articles
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
Ambrosy AP, Yang J, Sung SH, et al.
Journal:
J Am Heart Assoc

First published: October 8, 2021 DOI: 10.1161/JAHA.120.020377
View
- Share
Articles
Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model
Mohamad Dandan, Julia Han, Sabrina Mann, et al.
Journal:
Arteriosclerosis, Thrombosis, and Vascular Biology.

First published: October 7, 2021 DOI: 10.1161/ATVBAHA.121.316764
View
- Share
Articles
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi M, Kontush A
Journal:
Biochim Biophys Acta Mol Cell Biol Lipids

First published: October 5, 2021 DOI: 10.1016/j.bbalip.2021.159058
View
- Share

1 2

Oct 2021 Articles

Articles

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Majithia A, Bhatt DL, Friedman AN, et al.

Articles

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG

Verma S, Bhatt DL, Steg PG, et al.

Articles

European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology

Suleman Aktaa, Baris Gencer, Elena Arbelo, et al.

Articles

Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

Azita H Talasaz, Ai-Chen Jane Ho, Fawzia Bhatty, et al.

Articles

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, et al.

Articles

Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT

Kazuma Oyama, Robert P Giugliano, Michael A Blazing et al.

Articles

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Kausik K Ray, Laurens F Reeskamp, Ulrich Laufs, et al.

Articles

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.

Articles

Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data

Kwon O, Na W, Hur J, et al.

Articles

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

Ambrosy AP, Yang J, Sung SH, et al.

Articles

Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model

Mohamad Dandan, Julia Han, Sabrina Mann, et al.

Articles

High-density lipoproteins (HDL): Novel function and therapeutic applications

Darabi M, Kontush A

Articles

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Majithia A, Bhatt DL, Friedman AN, et al.

Share

Articles

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG

Verma S, Bhatt DL, Steg PG, et al.

Share

Articles

European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology

Suleman Aktaa, Baris Gencer, Elena Arbelo, et al.

Share

Articles

Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

Azita H Talasaz, Ai-Chen Jane Ho, Fawzia Bhatty, et al.

Share

Articles

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, et al.

Share

Articles

Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT

Kazuma Oyama, Robert P Giugliano, Michael A Blazing et al.

Share

Articles

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Kausik K Ray, Laurens F Reeskamp, Ulrich Laufs, et al.

Share

Articles

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.

Share

Articles

Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data

Kwon O, Na W, Hur J, et al.

Share

Articles

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

Ambrosy AP, Yang J, Sung SH, et al.

Share

Articles

Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model

Mohamad Dandan, Julia Han, Sabrina Mann, et al.

Share

Articles

High-density lipoproteins (HDL): Novel function and therapeutic applications

Darabi M, Kontush A

Share